Monday, September 22, 2014

Dyax Corp. Highlights Recent Progress in Licensing and Funded …

Dyax Corp. (NASDAQ:DYAX) highlighted recent progress and upcoming milestones in its Licensing and Funded Research Portfolio (LFRP), including, most recently, licensee Eli Lilly and Company's announcement of the fourth positive Phase 3 study outcome for CYRAMZA™ (ramucirumab). More …